Mandate

VINGE ADVISES CARNEGIE IN CONNECTION WITH HANSA MEDICAL’S RIGHTS ISSUE AND BLOCK SALE OF FARSTORPS GÅRD’S SHARES

March 09, 2015

Hansa Medical has resolved to carry out a rights issue of MSEK 246 before deduction of issue related costs. The rights issue is fully guaranteed through subscription undertakings and underwriting. The proceeds from the issue will be used to finance the company’s future research and development activities. In connection herewith, the company also announced that Hansa Medical’s former majority shareholder, Farstorps Gård, has sold some of its holding to certain Swedish and international institutional owners.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes.. The company’s shares are admitted to trading on Nasdaq First North in Stockholm.

Vinge advised Carnegie which is the financial adviser in connection with the rights issue and sale. The team consists of Peter Bäärnhielm, Dain Nevonen and Sabina Börjesson.   

Related

Vinge advised Dr Schär

Vinge advised Dr Schär in the acquisition of Semper AB:s glutenfree business Dr. Schär, an Italian based company, is a developer of product for special nutritional needs.
February 29, 2024

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue
February 29, 2024

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with SBB establishing a joint venture company for community properties together with Castlelake, LP ("Castlelake").
February 29, 2024